Metastatic Prostate Cancer with Highest Reported PSA Level

Open access

Abstract

Introduction: Prostate cancer is the sixth most common cancer in the world, the second most common cancer among men, and the most common cancer in men in Europe. Metastatic prostate cancer among young patients represents the rarest of the newly diagnosed prostate cancer, with few reports of cases with a longer survival.

Case presentation: We present the case of a 59 year-old male who was referred with back pain over the last month. Digital rectal examination highlighted an enlarged and totally indurated prostate of 4x4.5 cm, while abdominopelvic X-rays showed osteoblastic metastases in the spine and pelvis bones. Laboratory examinations revealed a Prostate Specific Antigen level of 7941 ng/ml. Prostate biopsy histology showed a bilateral prostate cancer with a Gleason score of 8. Androgen deprivation therapy and daily administration of biphosphonates were prescribed. After two years of treatment, the Prostate Specific Antigen level decreases to 8 ng/ml.

Conclusions: We reported the highest Prostate Specific Antigen level in a patient under 60 years old with metastatic prostate cancer. Prostate cancer remains an important public health problem due to the aggressiveness of the disease and advanced stage upon diagnosis. Prostate Specific Antigen is mandatory to evaluate, to have a reference level in order to prevent metastatic prostate cancer in young patients at diagnosis.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Grönberg H. Prostate cancer epidemiology. Lancet Lond Engl. 2003;361(9360):859–864.

  • 2. Globocan 2012. Available from: http://globocan.iarc.fr/Default.aspx

  • 3. Benoit RM Naslund MJ. The socioeconomic implications of prostate-specific antigen screening. Urol Clin North Am. 1997;24(2):451–458.

  • 4. Krpina K Markić D Rahelić D Ahel J Rubinić N Španjol J. 10-year survival of a patient with metastatic prostate cancer: Case report and literature review. Arch Ital Urol Androl. 2015;87(3):252-3. doi: 10.4081/aiua.2015.3.252.

  • 5. Slipman CW Patel RK Siegelman ES et al. Metastatic prostate cancer to the spine and a PSA of 5666: a case report. Pain Physician. 2001;4(4):317–321.

  • 6. Persec Z Persec J Sović T Romic Z Bosnar Herak M Hrgovic Z. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21380 ng/ml. Onkologie. 2010;33(3):110–112. doi: 10.1159/000277743.

  • 7. Dantanarayana ND Hossack T Cozzi P et al. Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia. BMC Urol. 2015;15(1):124. doi: 10.1186/s12894-015-0117-3.

  • 8. Andriole GL Crawford ED Grubb RL et al. Prostate cancer screening in the randomized Prostate Lung Colorectal and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–132. doi: 10.1093/jnci/djr500.

  • 9. Schröder FH Hugosson J Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328. doi: 10.1056/NEJMoa0810084

  • 10. Buzzoni C Auvinen A Roobol MJ et al. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2015;68(5):885–890. doi: 10.1016/j.eururo.2015.02.042.

  • 11. Schröder FH Hugosson J Carlsson S et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012;62(5):745–752. doi: 10.1016/j.eururo.2012.05.068.

  • 12. Woolf SH. Public health perspective: the health policy implications of screening for prostate cancer. J Urol. 1994;152(5 Pt 2):1685–1688.

  • 13. Sun M Choueiri TK Hamnvik O-PR et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. 2016;2(4):500-507. doi: 10.1001/jamaoncol.2015.4917.

  • 14. Nyman CR Andersen JT Lodding P Sandin T Varenhorst E. The patient’s choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide a gonadotrophin-releasing hormone analogue or orchidectomy. BJU Int. 2005;96(7):1014–1018.

  • 15. Leidinger P Hart M Backes C et al. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level Gleason score or TNM status. Tumour Biol. 2016;37(8):10177-10185. doi: 10.1007/s13277-016-4883-7.

Search
Journal information
Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2204 1802 305
PDF Downloads 1116 897 230